CompletedPhase 3

Study Of Adults And Adolescents With Vasomotor Rhinitis

United States352 participantsStarted 2005-07-11

Plain-language summary

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Must be outpatients. * Diagnosis of VMR. * Literate in English or native language. Exclusion criteria: * Significant concomitant medical condition. * Use corticosteroids or other allergy medications during the study. * Used tobacco products within the past year.

What they're measuring

Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS)

Timeframe: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

Trial details

NCT IDNCT00117325

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2006-02-09

Results submitted2017-08-11

View on ClinicalTrials.gov More Rhinitis, Vasomotor trials